Editorial: fenofibrate as second-line therapy in high risk PBC - more answers or more questions? Authors' reply

被引：2

作者：

Cheung, A. C. ^{[1
]}

Kowgier, M. ^{[1
,2
]}

Feld, J. J. ^{[1
,3
]}

机构：

[1] Univ Toronto, Toronto Western & Gen Hosp, Univ Hlth Network, Toronto Ctr Liver Dis, Toronto, ON, Canada

[2] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada

[3] Univ Toronto, McLaughlin Rotman Ctr Global Hlth, Toronto, ON, Canada

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2016年 / 43卷 / 05期

关键词：

D O I：

10.1111/apt.13519

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：649 / 650

页数：2

共 3 条

[1] The UK-PBC Risk Scores: Derivation and Validation of a Scoring System for Long-Term Prediction of End-Stage Liver Disease in Primary Biliary Cholangitis [J].

Carbone, Marco ;

Sharp, Stephen J. ;

Flack, Steve ;

Paximadas, Dimitrios ;

Spiess, Kelly ;

Adgey, Carolyn ;

Griffiths, Laura ;

Lim, Reyna ;

Trembling, Paul ;

Williamson, Kate ;

Wareham, Nick J. ;

Aldersley, Mark ;

Bathgate, Andrew ;

Burroughs, Andrew K. ;

Heneghan, Michael A. ;

Neuberger, James M. ;

Thorburn, Douglas ;

Hirschfield, Gideon M. ;

Cordell, Heather J. ;

Alexander, Graeme J. ;

Jones, David E. J. ;

Sandford, Richard N. ;

Mells, George F. .

HEPATOLOGY, 2016, 63 (03) :930-950

[2] Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes [J].

Cheung, A. C. ;

Lapointe-Shaw, L. ;

Kowgier, M. ;

Meza-Cardona, J. ;

Hirschfield, G. M. ;

Janssen, H. L. A. ;

Feld, J. J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :283-293

[3] Editorial: fenofibrate as second-line therapy in high risk PBC - more answers or more questions? [J].

Jones, D. E. J. ;

Hansen, B. E. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (05) :648-649

← 1 →